{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:53:01Z","timestamp":1790949181337,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-025-02713-9","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T12:12:12Z","timestamp":1756296732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comprehensive one-day management of prostate cancer patients: PRO-FAST single-fraction ablative, urethral-sparing, HDR-like, robotic SBRT"],"prefix":"10.1186","volume":"20","clinical-trial-number":[{"clinical-trial-number":"nct05936736","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andrei","family":"Fodor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Torrisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Brombin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Broggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Losa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Maga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Mellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Martinenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Tummineri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Mangili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Lucrezia","family":"Deantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Tudda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Castriconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Maria Vittoria","family":"Rancoita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaclelia Stefania","family":"Di Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Gaboardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Di Muzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"2713_CR1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. Version 1.2025: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"key":"2713_CR2","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New Engl J Med. 2016;375:1415\u201324.","journal-title":"New Engl J Med"},{"key":"2713_CR3","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","volume":"375","author":"JL Donovan","year":"2016","unstructured":"Donovan JL, Hamdy FC, Lane JA, et al. Pateint-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375:1425\u201337.","journal-title":"N Engl J Med"},{"issue":"9","key":"2713_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, et al. Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119\u201334.","journal-title":"Ann Oncol"},{"issue":"3","key":"2713_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","volume":"119","author":"PJ Prada","year":"2016","unstructured":"Prada PJ, Cardenal J, Blanco AG, et al. High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cance: toxicity and long-term biochemical results. Radiother Oncol. 2016;119(3):411\u20136.","journal-title":"Radiother Oncol"},{"issue":"6","key":"2713_CR6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.brachy.2018.06.002","volume":"17","author":"PJ Prada","year":"2018","unstructured":"Prada PJ, Ferri M, Cardenal J, et al. High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: toxicity and 6-year biochemical results. Brachytherapy. 2018;17(6):845\u201351.","journal-title":"Brachytherapy"},{"key":"2713_CR7","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","volume":"53","author":"A Pollack","year":"2002","unstructured":"Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097\u2013105.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2713_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","volume":"70","author":"DA Kuban","year":"2008","unstructured":"Kuban DA, Tucker SL, Dong L, et al. Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phts. 2008;70:67\u201374.","journal-title":"Int J Radiat Oncol Biol Phts"},{"key":"2713_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13014-015-0419-3","volume":"10","author":"MD Hall","year":"2015","unstructured":"Hall MD, Schultheiss TE, Smith DD, et al. The impact of increasing dose on overall survival in prostate cancer. Radiat Oncol. 2015;10:115.","journal-title":"Radiat Oncol"},{"key":"2713_CR10","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","volume":"294","author":"AL Zietman","year":"2005","unstructured":"Zietman AL, De Silvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localised adenocarcinoma of the prostate. JAMA. 2005;294:1233\u20139.","journal-title":"JAMA"},{"key":"2713_CR11","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","volume":"80","author":"V Beckendorf","year":"2011","unstructured":"Beckendorf V, Guerif S, La Pris\u00e8 E, et al. 70 vs 80 Gy in localised prostate cancer: 5 year result of GETUG 06 randomised trial. Int J Radiat Oncol Biol Phys. 2011;80:1056\u201363.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2713_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA259","author":"C Hennequin","year":"2024","unstructured":"Hennequin C, Sargos P, Roca L, et al. Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.LBA259.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2713_CR13","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensi-ty-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047\u201360.","journal-title":"Lancet Oncol"},{"issue":"17","key":"2713_CR14","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35(17):1884\u201390.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2713_CR15","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","volume":"17","author":"L Incrocci","year":"2016","unstructured":"Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a random-ised, multicenter, open-label, phase 3 trial. Lancet Oncol. 2016;17(8):1061\u20139.","journal-title":"Lancet Oncol"},{"issue":"20","key":"2713_CR16","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, et al. Randomized phase 3 noninferiority study comparing two radio-therapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325\u201332.","journal-title":"J Clin Oncol"},{"issue":"31","key":"2713_CR17","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","volume":"31","author":"A Pollack","year":"2013","unstructured":"Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31(31):3860\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2713_CR18","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","volume":"43","author":"DJ Brenner","year":"1999","unstructured":"Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43(5):1095\u2013101.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2713_CR19","first-page":"1009","volume":"33","author":"JF Fowler","year":"2013","unstructured":"Fowler JF, Toma-Dasu I, Dasu A. Is the \u03b1\/\u03b2ratio for prostate tumors really low and does it vary with the level of risk at diagnosis? Anticancer Res. 2013;33(3):1009\u201311.","journal-title":"Anticancer Res"},{"key":"2713_CR20","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","volume":"82","author":"R Miralbell","year":"2012","unstructured":"Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: \u03b1\/\u03b2=1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys. 2012;82:e17\u201324.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2713_CR21","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","volume":"51","author":"A Dasu","year":"2012","unstructured":"Dasu A, Toma-Dasu I. Prostate alpha\/beta revisited \u2013 an analysis of clinical results from 14168 patients. Acta Oncol. 2012;51:963\u201374.","journal-title":"Acta Oncol"},{"issue":"2","key":"2713_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ijrobp.2022.08.030","volume":"115","author":"DH Brand","year":"2023","unstructured":"Brand DH, Bruningk SC, Wilkins A, et al. The fraction size sensitivity of late genitourinary toxicity: analysis of alpha\/beta (\u03b1\/\u03b2) ratios in the CHHiP trial. Int J Radiat Oncol Biol Phys. 2023;115(2):327\u201336.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2713_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1748-717X-8-118","volume":"8","author":"A Katz","year":"2013","unstructured":"Katz A, Santoro M, Diblasio F, et al. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol. 2013;8:118.","journal-title":"Radiat Oncol"},{"key":"2713_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","volume":"109","author":"CR King","year":"2013","unstructured":"King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013;109:217\u201321.","journal-title":"Radiother Oncol"},{"issue":"6","key":"2713_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.euo.2018.06.013","volume":"1","author":"DB Fuller","year":"2018","unstructured":"Fuller DB, Falchook AD, Crabtree T, et al. Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-year outcomes. Eur Urol Oncol. 2018;1(6):540\u20137. https:\/\/doi.org\/10.1016\/j.euo.2018.06.013.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"2713_CR26","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","volume":"102","author":"RM Meier","year":"2018","unstructured":"Meier RM, Bloch DA, Cotrutz C, et al. Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints. Int J Radiat Oncol Biol Phys. 2018;102(2):296\u2013303. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.05.040.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2713_CR27","doi-asserted-by":"publisher","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","volume":"2","author":"AU Kishan","year":"2019","unstructured":"Kishan AU, Dang A, Katz Aj, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Netw Open. 2019;2(2):e188006. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.8006.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2713_CR28","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","volume":"104","author":"WC Jackson","year":"2019","unstructured":"Jackson WC, Silva J, Hartman HE, et al. Stereotactic body radiotherapy for localized prostate cancer: a systematic review and meta-analysis of over 6000 patients treated on prospective stud-ies. Int J Radiat Oncol Biol Phys. 2019;104(4):778\u201389.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2713_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckmann L, et al. Ultrahypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394:385\u201395.","journal-title":"Lancet"},{"key":"2713_CR30","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","volume":"391","author":"N van As","year":"2024","unstructured":"van As N, Griffin C, Tree A, et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. N Engl J Med. 2024;391:1413\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2403365.","journal-title":"N Engl J Med"},{"issue":"6","key":"2713_CR31","first-page":"354","volume":"8","author":"SC Morgan","year":"2018","unstructured":"Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO and AUA evidence-based guideline. J Clin Oncol. 2018;8(6):354\u201360.","journal-title":"J Clin Oncol"},{"key":"2713_CR32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.radonc.2019.07.018","volume":"139","author":"T Zilli","year":"2019","unstructured":"Zilli T, Franzese C, Bottero M, et al. Single fraction urethra-sparing prostate cancer SBRT: phase i results of the ONE SHOT trial. Radiother Oncol. 2019;139:83\u20136.","journal-title":"Radiother Oncol"},{"issue":"5","key":"2713_CR33","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.ijrobp.2019.02.010","volume":"104","author":"ZA Siddiqui","year":"2019","unstructured":"Siddiqui ZA, Gustafson GS, Ye H, et al. Five-year outcomes of a single \u2013institution prospective trial of 19-Gy single \u2013fraction high-dose-rate brachytherapy for low-and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2019;104(5):1038\u201344.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2713_CR34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","volume":"146","author":"G Morton","year":"2020","unstructured":"Morton G, McGuffin M, Chung HT, et al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol. 2020;146:90\u20136.","journal-title":"Radiother Oncol"},{"key":"2713_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.radonc.2021.01.006","volume":"157","author":"S Armstrong","year":"2021","unstructured":"Armstrong S, Tsnag Y, Lowe G, et al. Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer. Radiother Oncol. 2021;157:93\u20138.","journal-title":"Radiother Oncol"},{"key":"2713_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0039","author":"C Greco","year":"2021","unstructured":"Greco C, Pares O, Pimentel N, et al. Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer. Results from the PROSINT phase 2 randomized clinical trial. JAMA Oncol. 2021. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0039.","journal-title":"JAMA Oncol"},{"key":"2713_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.01.004","author":"MJ Zelefsky","year":"2021","unstructured":"Zelefsky MJ, Yamada Y, Greco C, et al. Phase 3 multi-center, prospective, randomized trial compar-ing single-dose 24 Gy radiation therapy to a 3 -fraction SBRT regimen in the treatment of oligometa-static cancer. Int J Radiat Oncol Biol Phys. 2021. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.01.004.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2713_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","volume":"85","author":"IR Vogelius","year":"2013","unstructured":"Vogelius IR, Bentzen SM. Meta-analysis of the alfa\/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys. 2013;85(1):89\u201394.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"2713_CR39","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/0284186X.2018.1433874","volume":"57","author":"NR Datta","year":"2018","unstructured":"Datta NR, Stutz E, Rogers S, Bodis S. Clinical estimation of \u03b1\/\u03b2 values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy. Acta Oncol. 2018;57(7):883\u201394.","journal-title":"Acta Oncol"},{"key":"2713_CR40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","volume":"13","author":"CM van Leeuwen","year":"2018","unstructured":"van Leeuwen CM, Al O, Crezee J, et al. The alfa and beta of tumors: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol. 2018;13:96.","journal-title":"Radiat Oncol"},{"key":"2713_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.radonc.2019.08.027","volume":"141","author":"P Ghadjar","year":"2019","unstructured":"Ghadjar P, Fiorino C, Munck af Rosensch\u00f6ld P, et al. ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. Radiother Oncol. 2019;141:5\u201313.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2713_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage design for phase II clinical trials. Control Clin Trials. 1989;10(1):1\u201310.","journal-title":"Control Clin Trials"},{"key":"2713_CR43","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. November 27, 2017; https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"key":"2713_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2016.11.005","volume":"109","author":"MR Folkert","year":"2017","unstructured":"Folkert MR, Timmerman RD. Stereotactic ablative body radiosurgery (SABR) or stereotactic body radiation therapy (SBRT). Adv Drug Deliv Rev. 2017;109:3\u201314.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"2713_CR45","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1118\/1.1448823","volume":"29","author":"MJ Murphy","year":"2002","unstructured":"Murphy MJ. Fiducial-based targeting accuracy for external-beam radiotherapy. Med Phys. 2002;29(3):334\u201344.","journal-title":"Med Phys"},{"key":"2713_CR46","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/153303460700600601","volume":"6","author":"KH Wong","year":"2007","unstructured":"Wong KH, Dieterich S, Tang J, Cleary K. Quantitative measurement of CyberKnife robotic arm steering. Technol Cancer Res Treat. 2007;6:589\u201394.","journal-title":"Technol Cancer Res Treat"},{"issue":"3","key":"2713_CR47","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S1470-2045(24)00720-4","volume":"26","author":"J Nikitas","year":"2025","unstructured":"Nikitas J, Jamshidian P, Tree AC, et al. The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials. Lancet Oncol. 2025;26(3):378\u201386.","journal-title":"Lancet Oncol"},{"issue":"19","key":"2713_CR48","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.3390\/cancers13194970","volume":"13","author":"NG Di Muzio","year":"2021","unstructured":"Di Muzio NG, Deantoni CL, Brombin C, et al. Ten year results of extensive nodal radiotherapy and moderately hypofractionated simultaneous integrated boost in unfavorable intermediate-, high-, and very high-risk prostate cancer. Cancers. 2021;13(19):4970.","journal-title":"Cancers"},{"key":"2713_CR49","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2022.10.026","volume":"178","author":"K Cocks","year":"2023","unstructured":"Cocks K, Wells JR, Johnson C, et al. Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. Eur J Cancer. 2023;178:128\u201338.","journal-title":"Eur J Cancer"},{"issue":"16","key":"2713_CR50","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1016\/j.ejca.2008.07.030","volume":"44","author":"G van Andel","year":"2008","unstructured":"van Andel G, Bottomley A, Fossa SD, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44(16):2418\u201324.","journal-title":"Eur J Cancer"},{"issue":"5","key":"2713_CR51","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry MJ, Fowler FJ, O\u2019Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549\u201357.","journal-title":"J Urol"},{"issue":"6","key":"2713_CR52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","volume":"11","author":"RC Rosen","year":"1999","unstructured":"Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11(6):319\u201326.","journal-title":"Int J Impot Res"},{"issue":"1","key":"2713_CR53","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12955-019-1214-x","volume":"17","author":"C Marzorati","year":"2019","unstructured":"Marzorati C, Monzani D, Mazzocco K, et al. Validation of the Italian version of the abbreviated expanded prostate Cancer index composite (EPIC-26) in men with prostate Cancer. Health Qual Life Outcomes. 2019;17(1):147.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"2713_CR54","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1148\/radiol.2020191145","volume":"295","author":"A Zwanenburg","year":"2020","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295(2):328\u201338. https:\/\/doi.org\/10.1148\/radiol.2020191145.","journal-title":"Radiology"},{"issue":"4","key":"2713_CR55","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0360-3016(03)00132-9","volume":"56","author":"J Fowler","year":"2003","unstructured":"Fowler J, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys. 2003;56(4):1093\u2013104.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"2713_CR56","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1200\/JCO.20.03282","volume":"39","author":"V Murthy","year":"2021","unstructured":"Murthy V, Maitre P, Kannan S, et al. Prostate-oncly versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol. 2021;39(11):1234\u201342.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2713_CR57","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41391-021-00432-2","volume":"25","author":"T Jiang","year":"2022","unstructured":"Jiang T, Markovic D, Patel J, et al. Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. Prostate Cancer Prostatic Dis. 2022;25(1):126\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2713_CR58","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1186\/s12872-024-04421-w","volume":"24","author":"AA Khorram","year":"2024","unstructured":"Khorram AA, Pourasgharian R, Shams AS, et al. Androgen deprivation therapy use and the risk of heart failure in patients with prostate cancer: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2024;24:756.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"2713_CR59","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000496980","volume":"103","author":"A Antonelli","year":"2019","unstructured":"Antonelli A, Palumbo C, Noale M, et al. Impact of surgical approach on patient-reported outcomes after radical prostatectomy: a propensity score-weighted analysis from a multicenter, prospective, observational study (the Pros-IT CNR study). Urol Int. 2019;103(1):8\u201318.","journal-title":"Urol Int"},{"key":"2713_CR60","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.eururo.2024.08.030","volume":"86","author":"N van As","year":"2024","unstructured":"van As N, Yasar B, Griffin C, et al. Radical prostatectomy versus stereotactic radiotherapy for clinically localized prostate cancer: results of the PACE-A randomized trial. Eur Urol. 2024;86:566\u201376.","journal-title":"Eur Urol"},{"issue":"3","key":"2713_CR61","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","volume":"9","author":"AU Kishan","year":"2023","unstructured":"Kishan AU, Ma TM, Lamb JM, et al. Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial. JAMA Oncol. 2023;9(3):365\u201373.","journal-title":"JAMA Oncol"},{"key":"2713_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.01.014","author":"R Ratnakumaran","year":"2025","unstructured":"Ratnakumaran R, Sasitharan A, Khan A, et al. Dosimetric comparison of CyberKnife and conventional linac prostate stereotactic body radiation therapy plans: analysis of the PACE-B study. Int J Radiat Oncol Biol Phys. 2025. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.014.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2713_CR63","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.ijrobp.2024.06.030","volume":"120","author":"S Arcangeli","year":"2024","unstructured":"Arcangeli S, Chissotti C, Ferrario F, et al. Ablative radiation therapy for unfavorable prostate tumors (ABRUPT): preliminary analysis of toxicity and quality of life from a prospective study. Int J Radiat Oncol Biol Phys. 2024;120(5):1394\u2013403.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"2713_CR64","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1001\/jamaoncol.2021.2691","volume":"7","author":"BS Squires","year":"2021","unstructured":"Squires BS, Krauss DJ. Single-dose radiotherapy for prostate cancer- lessons learned from single-fraction high-dose-rate brachytherapy. JAMA Oncol. 2021;7(10):1572.","journal-title":"JAMA Oncol"},{"issue":"2","key":"2713_CR65","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.brachy.2017.10.001","volume":"17","author":"LC Mendez","year":"2018","unstructured":"Mendez LC, Ravi A, Chung H, et al. Pattern of relapse and dose received by the recurrent in-traprostatic nodule in low-to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy. Brachytherapy. 2018;17(2):291\u20137.","journal-title":"Brachytherapy"},{"issue":"1","key":"2713_CR66","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","volume":"124","author":"P Hoskin","year":"2017","unstructured":"Hoskin P, Rojas A, Ostler P, Hughes R, Alonzi R, Lowe G. Single \u2013dose high-dose-rate brachy-therapy compared to two and three fractions for locally advanced prostate cancer. Radiother Oncol. 2017;124(1):56\u201360.","journal-title":"Radiother Oncol"},{"issue":"Suppl 1","key":"2713_CR67","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.1016\/j.brachy.2016.04.301","volume":"15","author":"M Roos","year":"2016","unstructured":"Roos M, Kolkman-Deurloo I-K, de Pan C, Aluwini S. Single fraction HDR brachytherapy as mono-therapy in patients with prostate cancer: what is the optimal dose level? Brachytherapy. 2016;15(Suppl 1):S167\u20138.","journal-title":"Brachytherapy"},{"issue":"11","key":"2713_CR68","doi-asserted-by":"publisher","first-page":"S972","DOI":"10.1016\/S0167-8140(17)32130-8","volume":"123","author":"S Ruiz Arrebola","year":"2017","unstructured":"Ruiz Arrebola S, Tornero-Lopez AM, De la Vega JM, Prada PJ, Guirado D. What is the proper dose in single fraction HDR brachytherapy as monotherapy for prostate cancer EP-1768 at ESTRO 36 2017. Radiother Oncol. 2017;123(11):S972\u20133.","journal-title":"Radiother Oncol"},{"issue":"6","key":"2713_CR69","doi-asserted-by":"publisher","first-page":"786","DOI":"10.2967\/jnumed.118.219501","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Goodman JZ, Allen IE, et al. Metaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019;60(6):786\u201393.","journal-title":"J Nucl Med"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02713-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02713-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02713-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:43:44Z","timestamp":1757479424000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02713-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2713"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02713-9","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the present study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies using animals performed by any of the authors. This study has been approved by the Institutional Scientific Board of the IRCCS San Raffaele Scientific Institute (registration number 27\/INT\/\/2023). All participants will sign an Informed Consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Miriam Torrisi and Roberta Tummineri received a speaker honorarium from Accuray Inc. independently from the current work. Laura Giannini received a research fellowship from AIRC: IG 25951-project \u201cToward clinical use of PET in selecting patients with pancreatic cancer for local treatment intensification\u201d. Miriam Torrisi received a research grant from the Next Generation EU (PNRR-MCNT2-2023-12378239), with a project entitled \u201cRadio-immunotherapy in solid tumors\u201d (CUP Code: C43C24000320005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The remaining authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}